Skip to Main Content

The European Commission has opened an investigation into allegations that Vifor Pharma spread misleading information about a rival treatment to its blockbuster drug for iron deficiency, the latest sign of governments cracking down on anticompetitive practices in the pharmaceutical industry.

In a statement, the EC explained that Vifor may have disparaged its “closet and, potentially, only” competitor to its Ferinject medicine in the European market. Specifically, the global drug company ran a “misleading communication campaign,” primarily targeting health care providers, about a treatment sold by Pharmacosmos, a small, family run company based in Denmark.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


Create a display name to comment

This name will appear with your comment